Rigel Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Rigel Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Rigel Pharmaceuticals Inc Strategy Report
- Understand Rigel Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Rigel Pharmaceuticals Inc (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer, and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. The company’s lead product, the US FDA approved Tavalisse (fostamatinib disodium hexahydrate), is an oral spleen tyrosine kinase inhibitor to treat adult patients with chronic immune thrombocytopenia; and Rezlidhia (olutasidenib) for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation. Rigel is also evaluating Fostamatinib for autoimmune hemolytic anemia and IgA nephropathy in Phase II trials. The company has partnered clinical programs with Aclaris, BerGenBio, Daiichi, AstraZeneca, Kissei, Grifols, Merck and Novartis. Rigel is headquartered in South San Francisco, California, the US.
Rigel Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products |
---|
- |
Tavalisse (fostamatinib disodium hexahydrate): |
Chronic Immune Thrombocytopenic Purpura (ITP) |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In February, the company entered into an agreement to acquire the US rights to GAVRETO from Blueprint Medicines Corporation. |
2023 | Contracts/Agreements | In December, the company entered into an agreement with The University of Texas MD Anderson Cancer Center to further investigate REZLIDHIA in acute myeloid leukemia (AML) and other hematologic malignancies. |
2023 | Regulatory Approval | In January, the company’s REZLIDHIA (olutasidenib) has been added to National Comprehensive Cancer Network for the treatment of acute myeloid leukemia (AML). |
Competitor Comparison
Key Parameters | Rigel Pharmaceuticals Inc | AbbVie Inc | Novartis AG | Amgen Inc | Gilead Sciences Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
City | South San Francisco | North Chicago | Basel | Thousand Oaks | Foster City |
State/Province | California | Illinois | - | California | California |
No. of Employees | 147 | 50,000 | 76,057 | 26,700 | 18,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Gary A. Lyons | Chairman | Executive Board | 2014 | 71 |
Raul R. Rodriguez | President; Chief Executive Officer | Executive Board | 2014 | 62 |
Dean L. Schorno | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | 60 |
Wolfgang Dummer, MD, PhD | Chief Medical Officer; Executive Vice President | Senior Management | 2019 | 57 |
David A. Santos | Chief Commercial Officer; Executive Vice President | Senior Management | 2020 | 60 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward